Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide
1996

Resistance to Etoposide in Yeast Due to Inactive Topoisomerase II

publication Evidence: moderate

Author Information

Author(s): YS Vassetzky, G-C Alghisi, E Roberts, SM Gasser

Primary Institution: Swiss Institute for Experimental Cancer Research (ISREC)

Hypothesis

How do inactive forms of topoisomerase II influence resistance to etoposide in yeast?

Conclusion

Inactive forms of topoisomerase II can confer resistance to etoposide in yeast cells.

Supporting Evidence

  • Truncated forms of topoisomerase II render yeast resistant to etoposide.
  • Maximal resistance is conferred by the full-length enzyme carrying a mutated active site.
  • Inactive forms of topoisomerase II do not complement a temperature-sensitive top2 mutation.

Takeaway

Some yeast can survive better against a cancer drug called etoposide if they have a broken version of a protein that usually helps the drug work.

Methodology

The study involved expressing various mutant forms of yeast topoisomerase II in yeast cells and testing their resistance to etoposide.

Limitations

The study primarily focuses on yeast, which may not fully represent human cancer cell behavior.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication